293 related articles for article (PubMed ID: 2535960)
21. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
Yao K; Godwin AK; Ozols RF; Hamilton TC; O'Dwyer PJ
Cancer Res; 1993 Aug; 53(16):3662-6. PubMed ID: 8101766
[TBL] [Abstract][Full Text] [Related]
22. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
Bertsche U; Schorn H
Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339
[TBL] [Abstract][Full Text] [Related]
23. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
[TBL] [Abstract][Full Text] [Related]
24. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion.
Andrews PA; Murphy MP; Howell SB
Cancer Res; 1985 Dec; 45(12 Pt 1):6250-3. PubMed ID: 4063975
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
Kable EP; Favier D; Parsons PG
Cancer Res; 1989 May; 49(9):2327-31. PubMed ID: 2706620
[TBL] [Abstract][Full Text] [Related]
26. Radiation-induced damage to DNA in drug- and radiation-resistant sublines of a human breast cancer cell line.
Alaoui-Jamali MA; Batist G; Lehnert S
Radiat Res; 1992 Jan; 129(1):37-42. PubMed ID: 1728055
[TBL] [Abstract][Full Text] [Related]
27. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
Kang YJ
Cell Mol Biol Res; 1995; 41(2):131-6. PubMed ID: 8581064
[TBL] [Abstract][Full Text] [Related]
28. Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
Evans CG; Bodell WJ; Tokuda K; Doane-Setzer P; Smith MT
Cancer Res; 1987 May; 47(10):2525-30. PubMed ID: 2882834
[TBL] [Abstract][Full Text] [Related]
29. Enhanced glutathione peroxidase expression protects cells from hydroperoxides but not from radiation or doxorubicin.
Liebmann J; Fisher J; Lipschultz C; Kuno R; Kaufman DC
Cancer Res; 1995 Oct; 55(19):4465-70. PubMed ID: 7671261
[TBL] [Abstract][Full Text] [Related]
30. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
Hansson J; Edgren M; Ehrsson H; Ringborg U; Nilsson B
Cancer Res; 1988 Jan; 48(1):19-26. PubMed ID: 3334994
[TBL] [Abstract][Full Text] [Related]
31. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
Chen G; Zeller WJ
Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
[TBL] [Abstract][Full Text] [Related]
32. Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance.
Samuels BL; Murray JL; Cohen MB; Safa AR; Sinha BK; Townsend AJ; Beckett MA; Weichselbaum RR
Cancer Res; 1991 Jan; 51(2):521-7. PubMed ID: 1845955
[TBL] [Abstract][Full Text] [Related]
33. Glutathione depletion, radiosensitization, and misonidazole potentiation in hypoxic Chinese hamster ovary cells by buthionine sulfoximine.
Clark EP; Epp ER; Biaglow JE; Morse-Gaudio M; Zachgo E
Radiat Res; 1984 May; 98(2):370-80. PubMed ID: 6539482
[TBL] [Abstract][Full Text] [Related]
34. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
Yang B; Keshelava N; Anderson CP; Reynolds CP
Cancer Res; 2003 Apr; 63(7):1520-6. PubMed ID: 12670899
[TBL] [Abstract][Full Text] [Related]
35. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
36. Protection from oxidative insult in glutathione depleted lens epithelial cells.
Reddan JR; Giblin FJ; Kadry R; Leverenz VR; Pena JT; Dziedzic DC
Exp Eye Res; 1999 Jan; 68(1):117-27. PubMed ID: 9986749
[TBL] [Abstract][Full Text] [Related]
37. Modulating activity of fullerol C60(OH)22 on doxorubicin-induced cytotoxicity.
Bogdanović G; Kojić V; Dordević A; Canadanović-Brunet J; Vojinović-Miloradov M; Baltić VV
Toxicol In Vitro; 2004 Oct; 18(5):629-37. PubMed ID: 15251181
[TBL] [Abstract][Full Text] [Related]
38. Modulation of glutathione level in cultured human melanoma cells.
Karg E; Brötell H; Rosengren E; Rorsman H
Acta Derm Venereol; 1989; 69(2):137-41. PubMed ID: 2564231
[TBL] [Abstract][Full Text] [Related]
39. alpha(v)beta(3) Integrin-mediated drug resistance in human laryngeal carcinoma cells is caused by glutathione-dependent elimination of drug-induced reactive oxidative species.
Brozovic A; Majhen D; Roje V; Mikac N; Jakopec S; Fritz G; Osmak M; Ambriovic-Ristov A
Mol Pharmacol; 2008 Jul; 74(1):298-306. PubMed ID: 18441044
[TBL] [Abstract][Full Text] [Related]
40. [Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].
Bier H
Laryngorhinootologie; 1990 Jan; 69(1):16-20. PubMed ID: 2310456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
